Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors.
Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood and appears to arise from developing striated muscle-forming cells. Since insulin-like growth factor II (IGF-II) is involved in normal muscle growth and maturation and elevated IGF-II mRNA levels have previously been reported in rhabdomyosarcomas, we have been studying the possible role of IGF-II in the unregulated growth and invasive potential of these embryonal tumors. In this study, we demonstrate that 13 of 14 rhabdomyosarcoma tumors express high levels of IGF-II mRNA relative to normal adult muscle and also express mRNA for the type I IGF receptors on their cell surface, the receptor thought to mediate the effects of IGF-II on muscle cells. We have established several rhabdomyosarcoma cell lines in mitogen-free media and demonstrate that these cells express type I IGF receptors on their cell surface and secrete IGF-II into the media. Exogenous IGF-II is able to stimulate cellular motility in these cell lines as assayed in a modified Boyden chamber. Finally, alpha IR-3, a type I receptor antagonist, inhibits the growth of these cell lines in serum-free media but does not inhibit IGF-II-induced motility of these cells. These data suggest that endogenously produced IGF-II functions as an autocrine growth and motility factor in many rhabdomyosarcoma tumors. The mitogenic actions of IGF-II are mediated through a domain of the type I IGF receptor that is blocked by alpha IR-3. IGF-II-induced motility may be mediated through an alternative signaling pathway.
El-Badry
O M
OM
Pediatric Branch, National Cancer Institute, Bethesda, Maryland 20892.
Minniti
C
C
Kohn
E C
EC
Houghton
P J
PJ
Daughaday
W H
WH
Helman
L J
LJ
D002455:Cell Division / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D006801:Humans; D007335:Insulin-Like Growth Factor II / Q000494:pharmacology / Q000502:physiology*; D009132:Muscles / Q000737:chemistry; D009363:Neoplasm Proteins / Q000502:physiology*; D012333:RNA, Messenger / Q000032:analysis; D012334:RNA, Neoplasm / Q000032:analysis; D017527:Receptor, IGF Type 2; D011956:Receptors, Cell Surface / Q000276:immunology / Q000378:metabolism; D017451:Receptors, Somatomedin; D012208:Rhabdomyosarcoma / Q000737:chemistry / Q000473:pathology*; D012983:Soft Tissue Neoplasms / Q000737:chemistry / Q000473:pathology*
D009363:Neoplasm Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D017527:Receptor, IGF Type 2; D011956:Receptors, Cell Surface; D017451:Receptors, Somatomedin; D007335:Insulin-Like Growth Factor II